U.S. Food and Drug Administration

 FDA News Release,  Nov 19, 2001

FDA Warns Consumers Not to Use the Dietary Supplement LipoKinetix.

The Food and Drug Administration (FDA) is warning consumers to immediately stop use of the product LipoKinetix^®, marketed as a dietary supplement by Syntrax Innovations, Inc. LipoKinetix has been implicated in a number of serious liver injuries. FDA has received multiple reports of persons who developed liver injury or liver failure while using LipoKinetix.

LipoKinetix is marketed for weight loss. It contains the ingredients norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of LipoKinetix. Liver injury developed between 2 weeks and 3 months of LipoKinetix use.

FDA urges consumers to discontinue use of LipoKinetix and consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. Consumers or health care professionals who are aware of adverse effects after the use of this or other dietary supplement products can report the adverse event to FDA’s MedWatch adverse event and product problem hot line at 1-800-FDA-1088.

Letter to Health Care Professionals.

The text in this article was prepared by the FDA Center for Food Safety and Applied Nutrition.